Ken Griffin Biomea Fusion, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$4.14 - $15.3 $188,370 - $696,150	-45,500 Reduced 19.86%	183,600 $826,000
Q1 2024 May 15, 2024	BUY	$13.92 - $19.5 $233,856 - $327,600	16,800 Added 7.91%	229,100 $3.43 Million
Q4 2023 Feb 14, 2024	BUY	$8.37 - $19.8 $1.35 Million - $3.2 Million	161,600 Added 318.74%	212,300 $3.08 Million
Q3 2023 Nov 14, 2023	BUY	$13.44 - $23.02 $193,536 - $331,488	14,400 Added 39.67%	50,700 $697,000
Q2 2023 Aug 14, 2023	BUY	$21.66 - $41.8 $314,070 - $606,100	14,500 Added 66.51%	36,300 $796,000
Q1 2023 May 15, 2023	BUY	$6.8 - $32.35 $86,360 - $410,845	12,700 Added 139.56%	21,800 $676,000
Q4 2022 Feb 14, 2023	BUY	$6.3 - $11.6 $57,330 - $105,560	9,100 New	9,100 $76,000

120

17.9M

978K

286K

Ticker BMEA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,290,600
Market Cap $230M
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.